A proposed method for the relative quantification of levels of circulating microRNAs in the plasma of gastric cancer patients

Abstract

Gastric cancer (GC) is the fifth most common type of malignancy and the third leading cause of cancer-associated mortality worldwide. It is necessary to identify novel methods aimed at improving the early diagnosis and treatment of GC. MicroRNA expression profiles in the plasma of patients with GC have demonstrated a potential use in the opportune diagnosis of this neoplasm. However, there are currently no standardized targets for use in the normalization of microRNA Cq values for different neoplasms. The present study tested two normalization approaches while analyzing plasma derived from patients with GC and non-atrophic gastritis. The first method utilized a panel of small nucleolar RNAs (snoRNAs) and a small nuclear RNA (snRNA) provided by a commercial array. The second normalization approach involved the use of hsa-miR-18a-5p and hsa-miR-29a-3p, which were identified by a stability analysis of the samples being tested. The results revealed that the snoRNAs and snRNA were not expressed in all samples tested. Only the stable microRNAs allowed a narrow distribution of the data and enabled the identification of specific downregulation of hsa-miR-200c-3p and hsa-miR-26b-5p in patients with GC. hsa-miR-200c-3p and hsa-miR-26b-5p have been previously linked to cancer, and a Kyoto Encyclopedia of Genes and Genomes analysis demonstrated that these microRNAs were associated with cell adhesion, cell cycle and cancer pathways.

Identification and validation of circulating miRNAs as endogenous controls in obstructive sleep apnea

“…Different studies previously used miR-186 [ 35 ], miR-106a [ 14 , 36 , 37 ], miR-29a [ 38 ] and miR-21 [ 39 ] as ECs in other diseases.…”

Analysis of the Differential Exosomal miRNAs of DC2.4 Dendritic Cells Induced by Toxoplasma gondii Infection

“…miR-99b-5p is associated with gastric cancer and involved in the regulation of the immune system [30], and may serve as a biomarker for communication in the immune system [31]. miR-212-3p is related to cancer and the immune system [32], and miR-3109-3p is involved in gastric cancer [33].…”

SOX9 promotes epithelial‑mesenchymal transition via the Hippo‑YAP signaling pathway in gastric carcinoma cells

“…Gastric cancer (GC) is the third major contributor of cancer mortality and the fifth most frequently diagnosed cancer in the world (1). GC led to >700,000 mortalities and resulted in 950,000 new cases of GC diagnosed in 2012 (2,3). The majority of patients with GC are diagnosed at a later stage and the five-year survival of GC ranges from 13.1 to 43.8% (4,5).…”